Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05498103 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Use of Methazolamide to Lower Intraocular Pressure

StatusActive, Not Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Recruiting to Active, Not Recruiting Primary completion date changed from estimate of Jul 31, 2023 to Sep 14, 2023 · Completion date: Aug 7, 2023 to Dec 2024 · Start date changed from estimate of Jan 1, 2023 to Feb 17, 2023 · 1 morev5 Show 4 more changesShow less
    • Primary completion date changed from estimate of Jul 31, 2023 to Sep 14, 2023
    • Completion date: Aug 7, 2023 to Dec 2024
    • Start date changed from estimate of Jan 1, 2023 to Feb 17, 2023
    • Site details revised
  2. Trial status: Not Yet Recruiting to Recruiting Start date: Aug 15, 2022 to Jan 1, 2023 · Site details revisedv4 Show 2 more changesShow less
    • Start date: Aug 15, 2022 to Jan 1, 2023
    • Site details revised
  3. Primary endpoint revisedv3 See this version in full on ClinicalTrials.gov ↗
  4. Primary endpoint revised Eligibility criteria shortened, about 134 words · Secondary endpoints shortened, about 26 wordsv2 Show 2 more changesShow less
    • Eligibility criteria shortened, about 134 words
    • Secondary endpoints shortened, about 26 words

    See this version in full on ClinicalTrials.gov ↗

  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the effect of methazolamide, 25 mg or 50 mg tablets once a day for a week than twice a day for a week, on lowering intraocular pressure and the safety of methazolamide.
Trial Details
NCT Number NCT05498103
Lead Sponsor University of Colorado, Denver
Conditions Glaucoma, Open-Angle
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov